45.95

2.45% 1.10

Livanova Plc (LIVN)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$44.85

Aprire:

$45.22

Volume 24 ore:

932.28K

Relative Volume:

1.15

Capitalizzazione di mercato:

$2.36B

Reddito:

$1.28B

Utile/perdita netta:

$-222.15M

Rapporto P/E:

-11.23

EPS:

-4.09

Flusso di cassa netto:

$145.52M

1 W Prestazione:

+6.24%

1M Prestazione:

+30.69%

6M Prestazione:

-7.56%

1 anno Prestazione:

-12.97%

Intervallo 1D:

$45.22

$46.11

Intervallo di 1 settimana:

$42.79

$46.11

Portata 52W:

$32.48

$57.35

Livanova Plc Stock (LIVN) Company Profile

Nome

Livanova Plc

Settore

Healthcare (1170)

Industria

Medical Devices (157)

Telefono

4402033250662

Indirizzo

20 EASTBOURNE TERRACE, LONDON

Dipendente

2,900

Cinguettio

Prossima data di guadagno

2024-10-30

Ultimi documenti SEC

LIVN's Discussions on Twitter

Confronta LIVN con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
LIVN Livanova Plc	45.95	2.36B	1.28B	-222.15M	145.52M	-4.09
ABT Abbott Laboratories	133.58	232.41B	42.34B	13.50B	6.66B	7.71
BSX Boston Scientific Corp	102.09	155.73B	17.55B	2.03B	2.72B	1.37
SYK Stryker Corp	383.89	146.23B	23.22B	2.86B	3.58B	7.40
MDT Medtronic Plc	87.44	106.37B	33.54B	4.66B	5.19B	3.62
EW Edwards Lifesciences Corp	77.52	45.88B	5.54B	4.18B	623.10M	7.00

Livanova Plc Stock (LIVN) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-05-20	Aggiornamento	Wolfe Research	Peer Perform → Outperform
2025-02-26	Downgrade	Wolfe Research	Outperform → Peer Perform
2024-10-04	Iniziato	Goldman	Buy
2024-09-17	Aggiornamento	Robert W. Baird	Neutral → Outperform
2024-03-20	Reiterato	Needham	Buy
2024-02-20	Aggiornamento	Mizuho	Neutral → Buy
2023-09-06	Iniziato	HSBC Securities	Hold
2023-07-19	Iniziato	Robert W. Baird	Neutral
2023-04-14	Iniziato	Mizuho	Neutral
2022-12-21	Iniziato	Barclays	Equal Weight
2022-04-06	Iniziato	Wolfe Research	Outperform
2022-02-24	Aggiornamento	UBS	Neutral → Buy
2021-12-03	Iniziato	Goldman	Buy
2021-08-20	Reiterato	Needham	Buy
2021-07-20	Aggiornamento	Needham	Hold → Buy
2021-03-03	Downgrade	Berenberg	Buy → Hold
2021-01-05	Downgrade	Needham	Buy → Hold
2020-09-02	Iniziato	Robert W. Baird	Outperform
2020-06-26	Reiterato	Needham	Buy
2019-10-30	Reiterato	Needham	Buy
2019-02-28	Reiterato	Needham	Buy
2018-11-28	Iniziato	UBS	Neutral
2018-08-02	Reiterato	Needham	Buy
2018-06-08	Iniziato	Stifel	Buy
2018-05-31	Reiterato	Needham	Buy
2018-02-28	Reiterato	Needham	Buy

Mostra tutto

Livanova Plc Borsa (LIVN) Ultime notizie

Jun 06, 2025

LivaNova completes epilepsy treatment study of VNS Therapy - Medical Device Network

Jun 06, 2025

Jun 05, 2025

LivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy - BioSpace

Jun 05, 2025

LivaNova at Jefferies Conference: Strategic Growth and Challenges - Investing.com

Jun 05, 2025

LivaNova at Jefferies Conference: Strategic Growth and Challenges By Investing.com - Investing.com UK

Jun 05, 2025

Artificial Heart Lung Machines Market Projected to Witness - openPR.com

Jun 05, 2025

LIVN Reports Promising Outcomes in Drug-Resistant Epilepsy Study - GuruFocus

Jun 05, 2025

LivaNova reports positive VNS Therapy study results for epilepsy - Investing.com

Jun 05, 2025

CORE-VNS Study Further Validates Effectiveness of LivaNova's VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy | LIVN Stock News - GuruFocus

Jun 05, 2025

LivaNova reports positive VNS Therapy study results for epilepsy By Investing.com - Investing.com UK

Jun 05, 2025

LivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy | LIVN Stock - GuruFocus

Jun 05, 2025